文献速递冠心病

COMFORTABLE AMI 试验五年临床结局与冠脉内影像发现:生物可降解聚合物 Biolimus 洗脱支架与裸金属支架在 ST 段抬高型心肌梗死患者中的随机比较

Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction.
PubMed 文献 · Eur Heart J · 2019-01-01

COMFORTABLE AMI 随机试验对 1157 例接受直接 PCI 的 STEMI 患者比较生物可降解聚合物 Biolimus 洗脱支架(BES,N=575)与裸金属支架(BMS,N=582),随访 5 年。BES 组主要不良心脏事件(MACE)风险显著低于 BMS 组(HR 0.56,95%CI 0.39-0.79,P=0.001),主要由靶血管相关再梗死和缺血驱动靶病变血运重建减少驱动;13 个月冠脉内影像显示两组血管愈合近乎完全。

要点

  • STEMI 直接 PCI 置入 BES 较 BMS 降低 5 年 MACE 风险(HR 0.56)。
  • 获益主要来自靶血管再梗死和缺血驱动靶病变血运重建减少。
  • 13 个月时两组支架段血管愈合近乎完全,极晚期明确支架血栓无差异。

核心结论

  • 在 STEMI 行直接 PCI 的患者中,置入生物可降解聚合物涂层 BES 较 BMS 降低 5 年 MACE 发生率,13 个月时靶病变血管愈合近乎完全且不依赖支架类型。

研究设计与样本

  • COMFORTABLE AMI 随机试验的 5 年临床随访,纳入 1157 例患者(BES N=575,BMS N=582)。
  • 对 103 例患者在基线和 13 个月随访时行 IVUS 和 OCT 连续冠脉内影像分析。

主要发现

  • 5 年时 BES 降低 MACE 风险(HR 0.56,95%CI 0.39-0.79,P=0.001)。
  • 靶血管相关再梗死风险降低(HR 0.44,95%CI 0.22-0.87,P=0.02)。
  • 缺血驱动靶病变血运重建风险降低(HR 0.41,95%CI 0.25-0.66,P<0.001)。
  • 明确支架血栓发生率 BES 2.2% 对 BMS 3.9%(HR 0.57,95%CI 0.28-1.16,P=0.12),极晚期明确支架血栓无差异(1.3% 对 1.6%,P=0.77)。
  • OCT 显示随访时支架梁贴壁不良频率无差异(BES 0.08% 对 BMS 0.02%,P=0.10),未覆盖支架梁少见但 BES 更常见(2.1% 对 0.15%,P<0.001)。

关键数值与推荐

  • IVUS 分析显示两组均无正向重构(外弹力膜面积变化 BES -0.63 mm2,95%CI -1.44 至 0.39;BMS -1.11 mm2,95%CI -2.27 至 0.04,P=0.07)。

临床怎么用

  • STEMI 直接 PCI 中选择生物可降解聚合物 BES 较 BMS 可降低 5 年 MACE 风险,支持使用该类 DES。
  • 13 个月时影像显示血管愈合近乎完全,极晚期支架血栓风险与 BMS 无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The long-term outcomes of biolimus-eluting stents (BESs) with biodegradable polymer as compared with bare-metal stent (BMS) in patients with ST-segment elevation myocardial infarction (STEMI) remain unknown. METHODS AND RESULTS: We performed a 5-year clinical follow-up of 1157 patients (BES: N = 575 and BMS: N = 582) included in the randomized COMFORTABLE AMI trial. Serial intracoronary imaging of stented segments using both intravascular ultrasound (IVUS) and optical coherence tomography performed at baseline and 13 months follow-up were analysed in 103 patients. At 5 years, BES reduced the risk of major adverse cardiac events [MACE; hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.39-0.79, P = 0.001], driven by lower risks for target vessel-related reinfarction (HR 0.44, 95% CI: 0.22-0.87, P = 0.02) and ischaemia-driven target lesion revascularization (HR 0.41, 95% CI: 0.25-0.66, P < 0.001). Definite stent thrombosis (ST) was recorded in 2.2% and 3.9% (HR 0.57, 95% CI: 0.28-1.16, P = 0.12) with no differences in rates of very late definite ST (1.3% vs. 1.6%, P = 0.77). Optical coherence tomography showed no difference in the frequency of malapposed stent struts at follow-up (BES 0.08% vs. BMS 0.02%, P = 0.10). Uncovered stent struts were rarely observed but more frequent in BES (2.1% vs. 0.15%, P < 0.001). In the IVUS analysis, there was no positive remodelling in either group (external elastic membrane area change BES: -0.63 mm2, 95% CI: -1.44 to 0.39 vs. BMS -1.11 mm2, 95% CI: -2.27 to 0.04, P = 0.07). CONCLUSION: Compared with BMS, the implantation of biodegradable polymer-coated BES resulted in a lower 5-year rate of MACE in patients with STEMI undergoing primary percutaneous coronary intervention. At 13 months, vascular healing in treated culprit lesions was almost complete irrespective of stent type. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00962416.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Räber L, Yamaji K, Kelbæk H, et al. Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2019. PMID: 30851032. doi:10.1093/eurheartj/ehz074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。